Work

Modeling cost-effectiveness analysis of treatment sequencing

Year: 2025

Type: article

Abstract: In clinical practice, patients with cancer often undergo treatment with a sequence of drugs, usually because of diminishing effectiveness over time or resistance development. However, few cost-effectiveness analyses have included that fact in their model. This paper aims at closing that gap by presenting a model that reflects the possibility of the patient switching from one therapeutic agent to another one throughout the long-term duration of his/her life. • Long-term diseases, like cancer, often need treatments with a sequence of drugs. • Markov model to assist physicians in choosing the best sequence of therapeutical agents. • Four non-absorbing states replicated with an index plus the absorbing state Death. • Cost-effectiveness analysis to evaluate the different possible sequences. • Application to the evaluation of different treatment pathways for relapsed ovarian cancer.

Source: Socio-Economic Planning Sciences

DOI: 10.1016/j.seps.2025.102210

Authors: Cristina del Campo, Jiaru Bai, L. Robin Keller

Institutions: Universidad Complutense de Madrid, Stony Brook University, University of California, Irvine

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,550